Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting

Phase 2

Pembrolizumab with GemcitabineTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04164082

Conditions

Bladder Flat Urothelial Carcinoma In Situ

Non-Muscle Invasive Bladder Urothelial Carcinoma

Stage 0a Bladder Cancer AJCC v8

Stage 0is Bladder Cancer AJCC v8

Stage I Bladder Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Cystoscopy

Gemcitabine Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-22. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-17.